COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
On Thursday, Novavax Inc (NASDAQ:NVAX) reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million.
週四，諾瓦瓦克斯醫藥（NASDAQ:NVAX）報告2024年第二季度銷售收入爲41500萬美元，而去年同期爲42400萬美元，未達到45860萬美元的共識。
Second quarter 2024 licensing, royalties, and other revenue include $391 million associated with the $500 million upfront payment received under the Sanofi SA (NASDAQ:SNY) agreement.
2024年第二季度的許可、版稅和其他收入中，包括與賽諾菲安萬特（NASDAQ:SNY）協議下收到的5000萬美元預付款有關的39100萬美元。
The COVID-19 vaccine maker reported EPS of $0.99, up from $0.58 a year ago, but it missed the consensus of $1.64.
這家COVID-19疫苗製造商報告的每股收益爲0.99美元，高於去年同期的0.58美元，但未達到1.64美元的共識。
Net income for the second quarter of 2024 was $162 million, compared to a net income of $58 million in the same period in 2023.
2024年第二季度的淨收入爲1.62億美元，而去年同期爲5800萬美元。
Also Read: Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern.
此外閱讀：諾瓦瓦克斯COVID-19疫苗有所喘息，與賽諾菲簽訂了億萬美元的協議，消除了其業績下行的疑慮。
"This is an exciting time for Novavax, and we have been keenly focused on evolving our operating model to leverage our key drivers of value," said John Jacobs, President and CEO.
「這是諾瓦瓦克斯令人興奮的時刻，我們一直專注於演變我們的運營模式，以利用我們的關鍵價值驅動器，」總裁兼CEO約翰·雅各布斯表示。
"We intend to drive future value for the business through not only the Sanofi partnership but also through our late-stage combination and influenza assets. We plan to unveil a new and expanded clinical pipeline by the end of this year and leverage both the pipeline and our proven technology to drive additional partnerships and deals and to ultimately drive significant, long-term value for our shareholders."
「我們打算通過不僅賽諾菲合作伙伴關係，而且還通過我們的晚期組合和流感資產推動未來的價值增長。我們計劃到今年年底之前推出新的和擴大的臨床流水線，並利用流水線和我們已證明的技術，推動額外的合作伙伴關係和交易，並最終爲我們的股東創造重大的、長期的價值。」
Guidance: Novavax expects 2024 revenue of $700 million – $800 million, including revenue recognition of Sanofi Payment, compared to the consensus of $936.38 million.
預測：諾瓦瓦克斯預計2024年收入爲7億美元-8億美元，包括賽諾菲支付的收入確認，而共識爲9363.8萬美元。
Earlier, the company expected sales of $970 million – $1.17 billion in combined revenue and Sanofi agreement payment.
此前，該公司預計在2024年實現銷售收入和賽諾菲協議付款的總額爲9700萬美元-11.7億美元。
The company expects 2024 product sales of $275 million – $375 million, reflecting approximately $100 million in Advance Purchase Agreements (APA) dose deliveries in 1H 2024 and $175 million to $275 million of commercial market sales expected in 2H 2024.
該公司預計2024年產品銷售額爲2.75億美元-3.75億美元，其中包括1H 2024的約1億美元的預購購買協議（APA）劑量交付以及2H 2024預計的1.75億美元至2.75億美元的商業市場銷售額。
Price Action: NVAX stock is up 6.26% at $11.38 at the last check on Thursday.
NVAX股票週四最後一次查看漲了6.26%，至11.38美元。
- Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September.
- 諾瓦瓦克斯股票盤前上漲，公司計劃在9月之前交付COVID-19疫苗。
Photo via Shutterstock
圖片來自shutterstock。
